Revenue Performance - Oncology services revenue for the three months ended October 31, 2021, was $11.8 million, a 16.5% increase from $10.1 million in the same period of 2020[111] - For the six months ended October 31, 2021, oncology services revenue reached $23.0 million, up 17.2% from $19.7 million in the prior year[111] Gross Margins - Gross margins for oncology services improved to 52.4% for the three months ended October 31, 2021, compared to 44.2% in the same period of 2020[112] Expenses - Research and development expenses increased by 39.3% to $2.3 million for the three months ended October 31, 2021, from $1.7 million in 2020[113] - Sales and marketing expenses rose by 21.7% to $1.6 million for the three months ended October 31, 2021, compared to $1.3 million in the same period of 2020[114] - General and administrative expenses increased by 34.5% to $2.0 million for the three months ended October 31, 2021, from $1.5 million in 2020[115] - Total costs and operating expenses for the six months ended October 31, 2021, were $22.9 million, a 16.9% increase from $19.6 million in 2020[110] Cash Flow and Financial Position - Net cash provided by operating activities was $1.4 million for the six months ended October 31, 2021, compared to $164,000 in the same period of 2020[118] - The company had an accumulated deficit of approximately $72.4 million as of October 31, 2021[107] - Cash on hand as of October 31, 2021, was $4.8 million, with working capital of $1.2 million[107]
Champions Oncology(CSBR) - 2022 Q2 - Quarterly Report